Royalty Report: Drugs, cardiac, Biotechnology – Collection: 29073

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • cardiac
  • Biotechnology
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Genome
  • Delivery
  • Technical Know How
  • Congestive Heart Failure
  • Medical
  • Device
  • Coating
  • Stent
  • Stem cells
  • Enzymes

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 25991

License Grant
As part of a License Agreement transaction, the Licensee acquired rights and corresponding obligations to the University.  Upon assumption, this agreement provides the Licensee with exclusive rights in the cardiac fields to develop and commercialize technology covered by the issued patent and patent applications that have been filed in the United States and in foreign countries.
License Property
The Technology covers development, manufacture, use and sale of gene therapy products for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure.
Field of Use
The Licensee develops products based on gene therapy, manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue engineering.

IPSCIO Record ID: 28042

License Grant
As part of Licensee's acquisition of the Licensor's portfolio of cardiovascular growth factor therapeutic assets, pursuant to a Technology Transfer Agreement entered into between the Licensor and the Licensee, Licensee acquired a portfolio of methods and compositions directed at the treatment of cardiovascular diseases. Licensee also has exclusive licenses to methods for introducing DNA to the heart and for improving heart muscle function, as well as to various biologics. The Licensee's resulting portfolio of cardiovascular product candidates and associated intellectual property include methods and genes applicable to the treatment of heart diseases, the promotion of healing, and the treatment of peripheral vascular disease. Among the product candidates we acquired  are Generx and Corgentin. Generx (alferminogene tadenovex) is a DNA-based, myocardial-derived growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. Angina, which is often felt as severe chest pain, can significantly limit patients’ mobility and quality of life and is a disorder that affects millions of adults in the United States and elsewhere.  In addition, we have secured the rights to Genvascor, a pre-clinical, DNA-based, endothelial nitric oxide synthase (eNOS) therapeutic.
License Property
Genvascor is being designed to induce production of nitric oxide and is directed at mediating the effects of multiple growth factors to enhance neovascularization and increased blood flow for the potential treatment of patients with critical limb ischemia due to advanced peripheral arterial occlusive disease (PAOD).
Field of Use
Licensee may elect to develop Genvascor alone or in collaboration with a development partner.

IPSCIO Record ID: 104737

License Grant
The Company is a party to a Technology Transfer Agreement between several Licensors which covers the transfer or license of certain assets and technology relating to (i) methods of gene therapy for the treatment of cardiovascular disease (including methods for the delivery of genes to the heart or vasculature and the use of angiogenic and/or non-angiogenic genes for the potential treatment of diseases of the heart or vasculature); (ii) therapeutic genes that include fibroblast growth factors (including FGF-4); insulin-like growth factors (including IGF-I); and potentially other related biologics; and (3) other technology and know-how, including manufacturing and formulation technology, as well as data relating to the clinical development of Generx and corresponding FDA regulatory matters.  On May 4, 2016, the successor in title consented to the sublicense of the license to an affiliate of the Company under the Technology Transfer Agreement.
Field of Use
This agreement pertains to the medical industry technology relating to (i) methods of gene therapy for the treatment of cardiovascular disease (including methods for the delivery of genes to the heart or vasculature and the use of angiogenic and/or non-angiogenic genes for the potential treatment of diseases of the heart or vasculature); (ii) therapeutic genes that include fibroblast growth factors (including FGF-4); insulin-like growth factors (including IGF-I); and potentially other related biologics; and (3) other technology and know-how, including manufacturing and formulation technology, as well as data relating to the clinical development of Generx and corresponding FDA regulatory matters.

IPSCIO Record ID: 530

License Grant
Licensor will grant Licensee an exclusive (even as to Licensor), worldwide, fully-paid, perpetual license (with the right to sublicense) under Licensor’s interest in any Collaboration Technology jointly owned by Licensor and Licensee necessary or useful to make, have made, import, use, offer for sale and sell Development Candidates (and corresponding Collaboration Products), subject to Article 15, for indications other than those which Licensor retains rights hereunder, and products other than Collaboration Products.
License Property
Collaboration Products refer to research, develop and commercialize gene-based products incorporating the VEGF gene for the treatment of coronary artery disease and peripheral vascular disease.  VEGF is a protein that stimulates the formation of new blood vessels and improves blood flow.
Field of Use
Field shall mean the research, drug discovery and development collaboration aimed at therapeutic agents useful for Gene Therapy-based induction of angiogenesis and for the first two years of the Research Program shall include all clinical indications; provided, thereafter the Field shall be limited to the treatment of coronary artery disease (CAD) and/or peripheral vascular disease (PVD) and/or those other specific clinical indications selected by Licensor pursuant to Section 2.5 below.

IPSCIO Record ID: 26103

License Grant
The asset purchased with the company is a novel gene therapy through preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF).
License Property
Licensor is an early-stage biotechnology company,effectively a single-product business, fully focusing on the further development of gene therapy approaches for cardiac disease.

IPSCIO Record ID: 5858

License Grant
The Licensor has granted the Licensee a non-revocable and exclusive worldwide license including the right to sublicense to third parties to the patents necessary to develop and commercialize drug candidates in which Cardio Vascu-Grow is the active ingredient. As a part of that agreement, Licensor will provide technical development services to us for the development and regulatory approvals of our drug candidates, including but not limited to, lab work, testing and production of our drug candidates in which Cardio Vascu-Grow is the active ingredient for clinical trials, all as directed by us.
License Property
We are working closely with an affiliated company, Cardio, pursuant to a joint patent and technology sharing agreement, to manufacture human fibroblast growth factor-1 (Cardio Vascu-Grow) for Cardio’s ongoing clinical trials.

Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients.  Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).

Issued US Patents
1. U.S. 6,268,178 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;” and
2. U.S. 6,642,026 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”
3. U.S. 6,773,899 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides”;
4. U.S. 6,794,162, entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;”
Pending US Patent Applications 1.. U.S. 10/649,480 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;” published as US Patent Application No. US 2004/0115769

Field of Use
Cardio Vascu-Grow™ stimulates the growth of new blood vessels, a biological process termed “angiogenesis”. This growth factor is being tested in a wide variety of human diseases that would benefit from increased angiogenesis including coronary artery disease, stroke, and peripheral vascular disease of the legs and wound healing.

IPSCIO Record ID: 7466

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

IPSCIO Record ID: 299236

License Grant
Under the initial agreement, the Canadian Licensor agreed to license on a co-exclusive certain patent rights, license rights, and technology.

This agreement is extending Licensee’s worldwide right and license to use, manufacture, have manufactured, distribute and sell, and to grant sublicenses to its Affiliates to use, manufacture, have manufactured, distribute and sell, the Licensor Technology in the Peripheral Vascular Field of Use and the GI Field of Use.

Licensor newly grants its licensee, the right for Licensee to have third party Distributors distribute Eligible Peripheral Vascular and/or GI Products.

This agreement is co-exclusive with an option to become exclusive.

License Property
This agreement is for paclitaxel or certain other agents as a coating for certain medical devices.

The license agreement regards paclitaxel-eluting stent products and related technologies.  Paclitaxel is released from the balloon or stent to prevent scar tissue formation in the blood vessel that can re-obstruct the artery (restenosis).

Field of Use
As used herein, the Coronary Vascular Field of Use means endoluminal vascular Licensed Applications for the treatment and/or prevention of disease of the coronary arteries and their branches, or other vasculature providing blood flow to the heart.

As used herein, the Peripheral Vascular Field of Use means the endoluminal vascular licensed applications for the treatment or preventionof disease of the peripheral blood vessels of the body.  Notwithstanding the foregoing, Peripheral Vascular Field of Use excludes any application in the Coronary Vascular Field of Use.  

GI Field of Use means the endoluminal licensed applications for the treatment or prevention of disease of the alimentary tract or liver.

IPSCIO Record ID: 255948

License Grant
This Agreement is for the Transfer and assign from Licensor to Licensee for all right, title, and interest to the patent and related clinical information covering LiprostinTM.
License Property
The pharmaceutical drug candidate is LiprostinTM for improving the effectiveness of current standard-of-care treatments related to endovascular interventions in the treatment of peripheral artery disease (PAD). LiprostinTM has completed FDA Phase I and three Phase II clinical trials, and we are evaluating several contract research organizations ('CRO') for completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase III.
Field of Use
The clinical stage patented pharmaceutical brand LiprostinTM is focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).
Peripheral artery disease is a narrowing of the peripheral arteries serving the legs, stomach, arms and head. (“Peripheral” in this case means away from the heart, in the outer regions of the body.) PAD most commonly affects arteries in the legs. Both PAD and coronary artery disease (CAD) are caused by atherosclerosis.

IPSCIO Record ID: 3533

License Grant
The Licensor and the Licensee entered into an Assignment and License Agreement, pursuant to which the Licensor granted the Licensee an exclusive, worldwide license and the assignment of patents relating to certain gene therapy applications of mSCF for the treatment of cardiac ischemia. The Licensee has the right to grant sublicenses to third parties under the agreement.
License Property
Licensor owns certain intellectual property (including an issued United States patent) relating to certain gene therapy methods for delivering stem cell factor coding sequences, in order to treat certain ischemic diseases.

The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.

The Licensor intellectual property and research involves gene therapy technologies.

Field of Use
The Licensee will use the rights to gene therapy applications for the membrane bound form of Stem Cell Factor, or mSCF, for treatment of cardiac ischemia.  Cardiac ischemia occurs when blood flow to your heart muscle is decreased by a partial or complete blockage of your heart's arteries. The decrease in blood flow reduces your heart's oxygen supply and can damage your heart muscle, reducing its ability to pump efficiently.

IPSCIO Record ID: 260407

License Grant
University grants to Licensee a license under Universitys interest in Patent Rights to make, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods in the Field, within the Territory and during the Term.  The amendment adds the patent information.

The licenses granted in this paragraph is exclusive with respect to the Field only.

License Property
The patent is for the therapy treatment or prevention of cardiovascular disease.
Field of Use
The Field means gene therapy for the treatment or prevention of cardiovascular diseases by the delivery of a gene or a synthetic equivalent (DNA, deoxyribonucleic acid or polydeoxyribonucleotide sequence), in whole or in part or in combination, including those encoding one or more phospholamban genes and/or SERCA-2 (sacroplasmic reticulum calcium ATPase) genes, or their mutants, excepting the involvement of anti-sense RNA (ribonucleic acid or polyribonucleotide sequence) of the phospholamban gene.

IPSCIO Record ID: 25872

License Grant
The Licensee entered into an agreement with the University pursuant to which the University granted the Licensee an exclusive license with the right to sublicense, in the United States, and in foreign countries where the respective patent rights exist, to certain technology  based on scientific discovery research conducted at a laboratory at the University, relating to angiogenic gene therapy for congestive heart failure.
Field of Use
The rights granted apply to the heart.

IPSCIO Record ID: 4994

License Grant
The Company has an exclusively license for patents and a patent application for the composition and production of the stable prostacyclin analog now known as UT-15 for the treatment of pulmonary hypertension and congestive heart failure and for late-stage peripheral vascular disease.

IPSCIO Record ID: 28242

License Grant
The University Board hereby grants to Licensee a royalty-bearing, exclusive worldwide license under licensed subject matter to manufacture, have manufactured, import, use, offer for sale and/or sell licensed products for use within field.
License Property
GENE THERAPY means therapeutic use of a designated gene (including therapeutic use of a homolog or derivative, or gene product thereof) which may be incorporated into vectors or other carriers, in a pharmaceutical composition that is administered by in vivo delivery (i.e. introduced inside the body) or by ex vivo delivery (i.e. introduced into cells or other complexes outside of the body which are subsequently introduced into the body). GENE THERAPY specifically excludes ANTISENSE THERAPY.

ANTISENSE THERAPY means therapeutic use of oligonucleotides or modified oligonucleotides that bind in a sequence specific manner to DNA or mRNA.

Field of Use
Field means Gene Therapy for treatment of heart disease and heart failure.

IPSCIO Record ID: 248329

License Grant
The Canadian Licensor hereby grants to Licensee of Netherlands within the Field of Use, and Licensee accepts, the exclusive worldwide right, sublicense and privilege under the Licensor Licensed Rights to use the Licensor Licensed Technology and to use, manufacture, distribute and sell Licensed Products.  Licensee shall sponsor the research Project as defined in the Collaborative Research Agreement between Licensor and University and, for that purpose, Licensee and Licensor entered into Heads of Agreement effective August 1, 2000.
License Property
Project means the project description entitled “LPL Gene Therapy for LPL Deficiency”, which is attached to the Collaborative Research Agreement, including any amendments thereto which the Parties and University may mutually agree to, from time to time, of the Collaborative Research Agreement.

The scientific collaboration is in the area of LPL gene therapy in humans including all research and development required for establishing a successful clinical LPL gene therapy protocol.

Description of Technology
U.S. 5,658,729 – Lipolipase Mutation 291, Implication for Coronary Artery Disease
U.S.  SN 08/737,954 – Recombinant Viruses Preparation and use thereof in Gene Therapy

Field of Use
Field of Use means gene therapy being the treatment of a disease caused by the malfunction of a gene, by transduction of cells of the organism with the normal gene or genetically altered gene.

IPSCIO Record ID: 240469

License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised.  This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.

Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.

IPSCIO Record ID: 260408

License Grant
Licensor, an individual, hereby grants an exclusive, even as to Licensor, worldwide license, with the right to sublicense through multiple tiers of sublicense, under Licensors interest in the Licensed Patents for any purpose in the Field, including, without limitation, to develop, make, have made, use, sell, offer for sale, have sold and import Products in the Field.
License Property
The patent relates to methods for transferring genes into the heart and blood vessels.
Field of Use
The Field shall mean the treatment or prevention of heart failure using products that act by the delivery of genes encoding proteins whose role is to regulate calcium uptake or release in the sarcoplasmic reticulum.

IPSCIO Record ID: 289243

License Grant
The Licensor of Sweden grants an exclusive, worldwide license under the Licensed Licensor Patent Rights and Licensor Know-How to develop, make, use, import, export, offer for sale and sell, and to have developed, made, used, imported, exported, offered for sale and sold, the Licensed Products, with the right to grant sublicenses.
License Property
Licensor has developed the Compound as a therapeutic for the cardiovascular market.

The Compound means the Milano variant of Apolipoprotein A-1.

Licensed Product means any pharmaceutical product including the Compound as its active ingredient the manufacture, use or sale of which would infringe one of the issued, valid unexpired claims or one of the pending claims contained in the Licensor Patent Rights in any country or involves use of the Licensor Know-How.

Field of Use
The field of use is the development of novel anti-atherogenic therapies.

Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. Initially, there are generally no symptoms. When severe, it can result in coronary artery disease, stroke, peripheral artery disease, or kidney problems, depending on which arteries are affected.

IPSCIO Record ID: 328142

License Grant
The University grants
–  an exclusive license to make, have made, use, sell, offer to sell and import the Know-How in the Territory and within the Fields of Use; and,
–  an exclusive license of University’s Patent Rights, except for Patent Rights in University Case No. 2002.026H, in the Territory to make, have made, use, sell, offer to sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use; and
–  an exclusive license of University’s Patent Rights in University Case No. 2002.026H in the Territory to make, have made, use, sell, offer to sell and import any Licensed Products in the Fields of Use and to practice any Licensed Process in the Fields of Use.
License Property
Licensor has rights to technology relating to expression profiling in the intact human heart and a method of treating heart failure with bucindolol.

Bucindolol means the beta-adrenergic–receptor antagonist having the chemical formula 2-{2-hydroxy-
3{{2-(3-indolyl)-1,1-dimethylethyl}amino}propoxy}-benzonitrile hydrochloride, and its racemates, isomers, prodrugs, active metabolites, analogs and any pharmaceutically acceptable salt or complex thereof, and diagnostics used in connection with its prescription.

Bucindolol Invention shall mean an Invention relating solely to the use of Bucindolol as a therapeutic or as a diagnostic used solely in connection with the development of Bucindolol.

Patents are titled
Expression Profiling in the Intact Human Heart,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Alpha-le Adrenergic
     Receptor,
Methods for Treating Heart Failure with Bucindolol Based on Genetic Targeting of the Beta-1 Adrenergic
     Receptor, and,
Methods for Treatment with Bucindolol Based on Genetic Targeting.

Field of Use
Fields of use is all fields.

Licensee is focused on developing and commercializing genetically-targeted therapies for heart failure and other cardiovascular diseases.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.